Wird geladen...
One-year outcomes of Aflibercept for refractory diabetic macular edema in Bevacizumab nonresponders
PURPOSE: A sub-population of patients with diabetic macular edema (DME) responds less effectively to off-label use of Bevacizumab. Approval of Aflibercept for DME has offered Bevacizumab nonresponders an alternative therapeutic option. Herein, we investigate the anatomical and functional changes ass...
Gespeichert in:
| Veröffentlicht in: | Indian J Ophthalmol |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Wolters Kluwer - Medknow
2021
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7933844/ https://ncbi.nlm.nih.gov/pubmed/33463593 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/ijo.IJO_459_20 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|